Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto
01 Apr 2024
AcquisitionClinical Study
MORRISVILLE, N.C., April 1, 2024 /PRNewswire/ -- Caidya, a leading global, multi-therapeutic clinical research organization (CRO), is pleased to announce the establishment of its new legal entity, Caidya Canada Limited, and the opening of its new office in Toronto, Ontario. This strategic move marks a significant milestone in Caidya's expansion plans, as it aims to extend its global footprint and strengthen its position in the thriving Canadian biotech market.
Continue Reading
The decision to establish Caidya Canada Limited aligns with the company's long-term growth and talent acquisition strategy. Canada is a key player in the biotech industry, offering a supportive ecosystem, world-class research institutions, and a highly skilled talent pool. By establishing a presence in this dynamic market, Caidya aims to leverage these advantages to enhance its clinical trial services capabilities and foster collaborations with local partners. This expansion will also further Caidya's efforts to attract and retain best-in-class talent in North America.
Caidya establishes new legal entity, Caidya Canada Limited, and opens new office in Toronto, Ontario.
Post this
Dr. Lingshi Tan, CEO of Caidya, expressed enthusiasm about the company's expansion into Canada, stating, "We are thrilled to establish Caidya Canada Limited and open our new office in Toronto. This strategic move not only allows us to extend the reach of the Caidya brand but also positions us to tap into the immense potential of the Canadian biotech market. We look forward to collaborating with local stakeholders and contributing to the advancement of healthcare solutions in Canada."
Caidya Canada Limited will focus on supporting the development of scientific innovations in the biotech sector through provision of full clinical trial services, helping to accelerate the development and commercialization of groundbreaking healthcare solutions.
For media inquiries, please contact: Heather Varela, VP, Global Marketing and Communications, Caidya
Phone: 480-698-6439
Email: [email protected]
About Caidya
Caidya is a global, multi-therapeutic clinical research organization (CRO) dedicated to advancing healthcare innovation and accelerating the development of new therapies. With full-service capabilities and a strategic footprint in 23 countries and regions, our global network provides broad access to diverse patient populations across the Americas, Europe, and APAC. Caidya's in-depth therapeutic and operational expertise helps partners conduct studies with greater efficiency and confidence. Our commitment to excellence and data-driven decision-making ensures the highest quality standards across all phases of the drug development process.
Caidya provides comprehensive clinical trial services from regulatory strategy and submissions, clinical operations, biometrics, and quality management, through post-approval surveillance. Following the merger of dMed and Clinipace, Caidya launched with a clear purpose to liberate clinical research and bring life-changing therapies to our global community.
SOURCE Caidya
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.